Fig. 3

Tumor NK cell and CD8+ T cell infiltration inversely correlates with tumor growth following IC treatment. A/J mice bearing subcutaneous NXS2 tumors were treated with IT-IC, IV-IC, or control treatment. Mice were killed 4 days post-treatment initiation and tumors underwent quantitative histological (a, b) or flow cytometric analyses (c, d). a, b After immunohistochemistry, 5 distinct microscopic fields were counted in a blinded fashion within each mouse’s tumor. NKG2A/C/E+ cells (a) and CD8a+ cytotoxic T cells (b) as a percentage of total nucleated cells (TNCs) within the each mouse’s tumor are plotted against each mouse’s percent tumor growth. a, b represent data from 3 independent experiments, with an average of 18 mice total within each treatment group. Horizontal error bars represent standard error of the mean for subsamples within an individual mouse. c Post-treatment tumor leukocytes (CD45+ cells) as a percentage of total live nucleated cells (TNCs) are plotted against each mouse’s percent tumor growth. d Mice are stratified by treatment group and by tumor growth or shrinkage. Within each group, tumor immune cells (CD8+, NKp46+, F4/80+, CD4+) are shown as a percentage of tumor leukocytes (CD45+ cells). Asterisks in d compare tumor immune cell populations between IT-IC-treated mice whose tumor grew versus IT-IC-treated mice whose tumor shrank. c, d represent data from 6 independent experiments with an average of 19 mice total within each treatment group. Note, the IT-IC treatment group consists of 6 mice that had tumors shrink and 15 mice that had tumors grow